Envision Healthcare (EVHC) Earning Somewhat Favorable Press Coverage, Accern Reports

News coverage about Envision Healthcare (NYSE:EVHC) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Envision Healthcare earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.2484104765583 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

EVHC has been the subject of several research reports. Bank of America decreased their price target on shares of Envision Healthcare from $72.00 to $60.00 and set a “buy” rating for the company in a report on Monday, October 9th. ValuEngine cut shares of Envision Healthcare from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Citigroup cut shares of Envision Healthcare from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research note on Thursday, November 2nd. Mizuho set a $57.00 target price on shares of Envision Healthcare and gave the company a “hold” rating in a research note on Tuesday, October 31st. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $30.00 target price on shares of Envision Healthcare in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $40.73.

Shares of Envision Healthcare (NYSE:EVHC) opened at $34.81 on Thursday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.01 and a quick ratio of 3.00. Envision Healthcare has a one year low of $23.77 and a one year high of $73.00. The firm has a market cap of $4,240.00, a price-to-earnings ratio of -23.36, a PEG ratio of 0.93 and a beta of 0.57.

Envision Healthcare (NYSE:EVHC) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $0.73 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.81 by ($0.08). Envision Healthcare had a positive return on equity of 4.88% and a negative net margin of 6.39%. The firm had revenue of $1.99 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter in the previous year, the firm posted $1.13 earnings per share. Envision Healthcare’s quarterly revenue was up 142.0% compared to the same quarter last year. research analysts anticipate that Envision Healthcare will post 2.49 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2018/01/18/envision-healthcare-evhc-earning-somewhat-favorable-press-coverage-accern-reports.html.

About Envision Healthcare

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Insider Buying and Selling by Quarter for Envision Healthcare (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply